Evofem Biosciences (EVFM) Misses Q3 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Evofem Biosciences (EVFM) Reports Complete Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
November 8, 2018 6:51 AM ESTEvofem Biosciences, Inc., (NASDAQ: EVFM) today announced the last patient has completed her last visit in AMPOWER, the second Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid and potassium bitartrate), its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, for the prevention of pregnancy.
Amphora is an investigational, first-in-class MVP-R designed to give a woman control over some of the most intimate issues of her life and health. This non-hormonal, non-systemic vaginal gel is being developed for woman-controlled birth control as well as prevention of certain sexually transmitted infections... More
